NAAG peptidase inhibitors and their potential for diagnosis and therapy
about
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusProstate-specific membrane antigen as a target for cancer imaging and therapyThinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingTargeted therapy using nanotechnology: focus on cancerA high-resolution structure of ligand-free human glutamate carboxypeptidase IIStructural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate AnalogsInteractions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterizationBioisosterism of urea-based GCPII inhibitors: Synthesis and structure–activity relationship studiesA remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced LipophilicityTheragnostic ultrasound using microbubbles in the treatment of prostate cancerThe Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 DeficiencyNAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammationNAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide familyPhencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.ALTERED MERISTEM PROGRAM 1 is involved in development of seed dormancy in Arabidopsis.Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanismN-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2).GCPII imaging and cancer.Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase IISynthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine.Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors.Extracellular proteases as targets for drug developmentA targeted low molecular weight near-infrared fluorescent probe for prostate cancer.Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigenEffects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophreniaDevelopment of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs.Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disordersAltered neurochemical profile after traumatic brain injury: (1)H-MRS biomarkers of pathological mechanisms.Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalitiesN-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophreniaTargeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.Dysregulation of glutamate carboxypeptidase II in psychiatric disease.[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Bispecific small molecule-antibody conjugate targeting prostate cancer.
P2860
Q26774920-B193D2E1-F460-4E2E-A443-AAECECD888E3Q26799439-CA16BBB9-3BA7-44EF-BC23-3766AD6EA60EQ26864995-9E9D03D6-7A62-46BC-9B4D-91716694B268Q27023361-6DF8EDDB-580E-42D5-8B7D-70C02FE973D9Q27643940-AB4D6877-7B58-4EC7-AB63-F3270A5A3360Q27649737-AD0C000C-DF5B-4356-9B61-24757E2D6C8CQ27653047-27577E44-A51A-487E-B12F-8EA723A0A4D1Q27658096-E33529AC-86F6-4AFA-AAE2-42D4ABB6A425Q27664106-6965194F-5E0B-48EB-B7E1-26ADEC3409CBQ27674033-223F352C-DBFF-486E-AA06-91C45A22D55DQ28067216-2D748681-387D-4346-AA31-D0D8871D5BC4Q28830661-7EA31098-0B97-4AAD-9D06-06210B2E8E41Q30459203-D11B77C2-386C-461D-AE51-87CB749F436BQ30465008-D463DC6A-B3B9-4E99-8227-C954C7CC4F84Q30465259-9E40FAFC-1BFC-4441-86FD-D50878045CAFQ30491856-56DF81B9-14F0-4095-BC68-EA0CFE1254C3Q33351394-F7D2846F-702C-4ABF-8CD8-00F8C05B5101Q33601673-98EA4583-357E-4047-B3C4-E7117DAC15CCQ33789515-FAB34B30-E87C-439D-91B3-C74645645DDCQ33827632-BFE3ACD2-452A-454F-9559-58A1C69AC87EQ33957067-4FE3E7E5-391C-4895-916C-FA2EC86F0B1AQ34344595-252963C3-FF95-41E4-AA76-C5BB2B73194BQ34345914-8A5BB522-2212-46E2-A55F-493797F49DE0Q34378304-532E9118-9739-4509-90B4-4F0636FC6E21Q34774930-0D6B531C-B34E-4DC1-BD2B-3E197F968E18Q35116202-A19F20D2-4C89-497F-A294-06FD3D16C907Q35446801-E913282C-E247-4404-972F-521233F7616FQ35926706-0C0843AF-C9CE-4AE6-B20D-01BEB4BB31A7Q36052391-4B2DB7F6-531F-449D-9CA1-86ACF28B4EF3Q36363280-582A444D-2BEF-4DC2-86C6-76017DBE0F1AQ36381928-69D057AE-3223-45F3-BDD9-392058DFD39BQ36387362-FD32D1E8-2527-4205-9397-FEF95CBC29B3Q36459054-4EE0DF2F-056B-49EF-8A97-A8F7809887DCQ36460130-CA87C9EE-6A21-4C44-B437-A80D63542E3FQ36471469-645C00A9-91EA-4869-A40D-D5E1415FAD83Q36477594-C529CF2C-A9E5-4DD1-B1BA-4D9ADC507FFAQ36501550-EDF140C2-6CFC-4A47-B42A-DD48E2BF5381Q36527334-9439225D-268C-4FB5-AB7F-F54BDCB1F260Q36867784-16EAF89F-84CC-44BE-844F-F5D16059F0A7Q37276578-ABBE1CA5-86CD-4516-A2E0-1CF48DEE9675
P2860
NAAG peptidase inhibitors and their potential for diagnosis and therapy
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@ast
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@en
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@nl
type
label
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@ast
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@en
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@nl
prefLabel
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@ast
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@en
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@nl
P2093
P356
P1476
NAAG peptidase inhibitors and their potential for diagnosis and therapy
@en
P2093
Alan P Kozikowski
Joseph H Neale
Martin G Pomper
P2888
P304
P356
10.1038/NRD1903
P407
P577
2005-12-01T00:00:00Z